Advertisement

Rheumatology International

, Volume 35, Issue 7, pp 1225–1232 | Cite as

Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study

  • Artemis KoutsonikoliEmail author
  • Maria Trachana
  • Anna-Bettina Heidich
  • Vasiliki Galanopoulou
  • Polyxeni Pratsidou-Gertsi
  • Alexandros Garyphallos
Original Article - Observational Research

Abstract

The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity. After a median disease duration of 7.4 years, 17/47 patients (36 %) had developed damage (SDI > 0). The most frequent domains damaged were the ocular (41 %), neuropsychiatric (35 %) and peripheral vascular (35 %) one. Peripheral vascular and neuropsychiatric damage was seen more frequently during the first 5 years of the disease. Longer exposure to azathioprine was associated with higher SDI at the end of follow-up (β = 0.008 for every additional month of use, p = 0.041). The mean annual flare frequency was associated with a shorter time interval until the development of the first damage (hazard’s ratio, HR 2.38 for each unit of increase, p = 0.018), while hydroxychloroquine use was associated with longer time interval (HR 0.19, p = 0.007). The lower rates of damage accrual in this study compared to other cohorts might be due to milder disease phenotype in Greek Caucasian cSLE patients, prompt diagnosis and effective disease control. Damage was noticed early in the disease course, and one-third of patients had an SDI > 0 at study completion. Disease flares and a severe disease course leading to prolonged use of immunosuppressives were significant risk factors, while hydroxychloroquine use was protective against cSLE damage accrual.

Keywords

Childhood Lupus Damage SDI 

Notes

Acknowledgement

The authors wish to thank Dr G. Bertsias for his critical review of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR, Beristain-Manterola R, Maeno N, Takei S, Gerloni V, Spencer CH, Pratsidou-Gertsi P, Ruperto N, Pistorio A, Martini A (2003) Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 49:501–507CrossRefPubMedGoogle Scholar
  2. 2.
    Meislin AG, Rothfield N (1968) Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 42:37–49PubMedGoogle Scholar
  3. 3.
    Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL (2010) Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 62:599–608PubMedGoogle Scholar
  4. 4.
    Mina R, Brunner HI (2010) Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 36:53–80CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMedGoogle Scholar
  6. 6.
    Miettunen PM, Ortiz-Alvarez O, Petty RE, Cimaz R, Malleson PN, Cabral DA, Ensworth S, Tucker LB (2004) Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol 31:1650–1654PubMedGoogle Scholar
  7. 7.
    Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, Mongey AB, Strife CF, Graham TB, Passo MH (2006) Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 15:198–206CrossRefPubMedGoogle Scholar
  8. 8.
    Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk FE, Breedveld FC, Huizinga TW (1999) Childhood-onset Systemic Lupus Erythematosus: clinical presentation and prognosis in 31 patients. Scand J Rheumatol 28:222–226CrossRefPubMedGoogle Scholar
  9. 9.
    Lilleby V, Flatø B, Førre O (2005) Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 23:261–269PubMedGoogle Scholar
  10. 10.
    Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, Grassi S, Alpigiani MG, Barbano G, Janz-Junior LL, Martini A, Ravelli A (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15:515–520CrossRefPubMedGoogle Scholar
  11. 11.
    Descloux E, Durieu I, Cochat P, Vital-Durand D, Ninet J, Fabien N, Cimaz R (2009) Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford) 48:779–784CrossRefGoogle Scholar
  12. 12.
    Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRefPubMedGoogle Scholar
  13. 13.
    Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, Martini A, Ravelli A (2006) A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989–2996CrossRefPubMedGoogle Scholar
  14. 14.
    Salah S, Lotfy HM, Mokbel AN, Kaddah AM, Fahmy N (2011) Damage index in childhood-onset systemic lupus erythematosus in Egypt. Pediatr Rheumatol Online J 9:36CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Appenzeller S, Marini R, Costallat LT (2005) Damage did not independently influence mortality in childhood systemic lupus erythematosus. Rheumatol Int 25:619–624CrossRefPubMedGoogle Scholar
  16. 16.
    Uziel Y, Gorodnitski N, Mukamel M, Padeh S, Brik R, Barash J, Mevorach D, Berkun Y, Tauber T, Press J, Harel L, Navon P, Rubenstein M, Naparstek Y, Hashkes PJ, Pediatric Rheumatology Study Group Of Israel @ SLERI (2007) Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus. Lupus 16:142–146CrossRefPubMedGoogle Scholar
  17. 17.
    Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152:550–556CrossRefPubMedGoogle Scholar
  18. 18.
    Taddio A, Rossetto E, Rosé CD, Brescia AM, Bracaglia C, Cortis E, Rigante D, Stabile A, Montico M, Ronfani L, Ventura A, Lepore L (2010) Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. J Pediatr 156:972–977CrossRefPubMedGoogle Scholar
  19. 19.
    Hui-Yuen JS, Imundo LF, Avitabile C, Kahn PJ, Eichenfield AH, Levy DM (2011) Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus 20:952–959CrossRefPubMedGoogle Scholar
  20. 20.
    Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Archer N, Bailey K, Davidson J, Baildam EM, Cleary G, McCann LJ, Beresford MW, UK Juvenile-Onset Systemic Lupus Erythematosus Study Group (2012) Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 64:2356–2365CrossRefPubMedGoogle Scholar
  21. 21.
    Lee PP, Lee TL, Ho MH, Wong WH, Lau YL (2007) Recurrent major infections in juvenile-onset systemic lupus erythematosus—a close link with long-term disease damage. Rheumatology (Oxford) 46:1290–1296CrossRefGoogle Scholar
  22. 22.
    Al-Mayouf SM (2013) Systemic lupus erythematosus in Saudi children: long-term outcomes. Int J Rheum Dis 16:56–60CrossRefPubMedGoogle Scholar
  23. 23.
    Sutton EJ, Davidson JE, Bruce IN (2013) The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 43:352–361CrossRefPubMedGoogle Scholar
  24. 24.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
  25. 25.
    Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Brunner HI, Silverman ED, Bombardier C, Feldman BM (2003) European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 49:335–341CrossRefPubMedGoogle Scholar
  27. 27.
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:541–547PubMedGoogle Scholar
  28. 28.
    Lim LS, Lefebvre A, Benseler S, Silverman ED (2013) Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction. J Rheumatol 40:513–519CrossRefPubMedGoogle Scholar
  29. 29.
    Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F (2013) Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 33:809–813CrossRefPubMedGoogle Scholar
  30. 30.
    Avcin T, Silverman ED (2007) Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 16:627–633CrossRefPubMedGoogle Scholar
  31. 31.
    Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM, Lumina Study Group (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61:830–839CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Rygg M, Pistorio A, Ravelli A, Maghnie M, Di Iorgi N, Bader-Meunier B, Da Silva C, Roldan-Molina R, Barash J, Dracou C, Laloum SG, Jarosova K, Deslandre CJ, Koné-Paut I, Garofalo F, Press J, Sengler C, Tauber T, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2012) A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 71:511–517CrossRefPubMedGoogle Scholar
  34. 34.
    Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A, Kaziolas G, Vafiadou E, Pantelidou K, Karamitsos D, Kontelis L, Krachtis P, Nikolia Z, Kaskani E, Tavaniotou E, Antoniades C, Karanikolas G, Kontoyanni A, ESORDIG Study (2003) Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. J Rheumatol 30:1589–1601PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Artemis Koutsonikoli
    • 1
    Email author
  • Maria Trachana
    • 1
  • Anna-Bettina Heidich
    • 2
  • Vasiliki Galanopoulou
    • 3
  • Polyxeni Pratsidou-Gertsi
    • 1
  • Alexandros Garyphallos
    • 4
  1. 1.1st Department of Pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration HospitalAristotle UniversityThessalonikiGreece
  2. 2.Department of Hygiene and EpidemiologyAristotle UniversityThessalonikiGreece
  3. 3.Rheumatology DepartmentPapageorgiou HospitalThessalonikiGreece
  4. 4.4th Department of Internal Medicine, Hippokration HospitalAristotle UniversityThessalonikiGreece

Personalised recommendations